红球菌感染10年回顾性临床经验及抗菌药物敏感性分析
该单中心回顾性队列研究分析了2012年6月至2022年间红球菌感染的临床特征、微生物学及药敏试验。临床显著感染罕见,仅10例,多数由马红球菌引起,接受2-3药联合治疗2-6个月后临床反应良好。
要点
- 红球菌对阿莫西林/克拉维酸、头孢菌素和氨基糖苷类高水平耐药。
- 亚胺培南和万古霉素对马红球菌仍可作为合适的经验性治疗选择。
- 非马红球菌的药敏谱显著优于马红球菌。
核心结论
- 尽管红球菌对多种抗生素高水平耐药,亚胺培南和万古霉素仍是马红球菌合适的经验性治疗选择。
- 马红球菌与非马红球菌之间的药敏试验存在显著差异。
研究设计与样本
- 单中心回顾性队列研究,纳入2012年6月至2022年期间红球菌感染病例。
- 菌种鉴定采用Sanger 16S rRNA基因测序和/或基质辅助激光解吸电离飞行时间质谱,药敏试验采用琼脂稀释法。
主要发现
- 最常见菌种为马红球菌/霍氏红球菌、纹带红球菌和赤红球菌,19%仅鉴定至属水平。
- 对亚胺培南、万古霉素、利奈唑胺、利福平和克拉霉素的敏感性超过95%。
- 临床显著红球菌感染罕见,共诊断10例,多数由马红球菌引起。
关键数值与推荐
- 对亚胺培南、万古霉素、利奈唑胺、利福平和克拉霉素的敏感性超过95%。
- 大多数患者接受2药或3药联合治疗,疗程2-6个月,临床反应良好。
临床怎么用
- 对于马红球菌感染,亚胺培南和万古霉素可作为经验性治疗选择。
- 临床显著红球菌感染罕见,治疗多采用2-3药联合方案,疗程2-6个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rhodococcus equi is an opportunistic pathogen known to cause pulmonary and extrapulmonary disease among immunocompromised patients. Treatment is frequently challenging due to intrinsic resistance to multiple antibiotic classes. While non-equi Rhodococcus spp. are prevalent, their clinical significance is poorly defined. There is also limited data on antibiotic susceptibility testing (AST) of Rhodococcus infection in humans. We conducted a single-center, retrospective cohort study evaluating clinical characteristics, microbiologic profile, and AST of Rhodococcus infections between June 2012 and 2022 at our tertiary academic medical center. Identification of Rhodococcus spp. was performed by Sanger 16S rRNA gene sequencing and/or matrix-assisted laser desorption ionization-time of flight mass spectrometry, and AST was performed by agar dilution. Three hundred twenty-two isolates of Rhodococcus spp. were identified from blood (50%), pulmonary (26%), and bone/joint (12%) sources. R. equi/hoagii, R. corynebacterioides, and R. erythropolis were the most frequently isolated species, with 19% of isolates identified only to genus level. One hundred ninety-nine isolates evaluated for AST demonstrated high-level resistance to amoxicillin/clavulanate, cephalosporins, and aminoglycosides. More than 95% susceptibility to imipenem, vancomycin, linezolid, rifampin, and clarithromycin was observed. Non-equi species showed a significantly more favorable AST profile relative to R. equi. Clinically significant Rhodococcus infection was rare with 10 cases diagnosed (majority due to R. equi) and managed. The majority of patients received 2- or 3-drug combination therapy for 2-6 months, with favorable clinical response. Significant differences in AST were observed between R. equi and non-equi species. Despite high antimicrobial resistance to several antibiotic classes, imipenem and vancomycin remain appropriate empiric treatment options for R. equi. Future research evaluating mechanisms underlying antimicrobial resistance is warranted.
引用
- Ranganath N, Mendoza MA, Stevens R, et al. Rhodococcus infection: a 10-year retrospective analysis of clinical experience and antimicrobial susceptibility profile. J Clin Microbiol. 2024. PMID: 38349145. doi:10.1128/jcm.01537-23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。